Fact based stock research
Takeda Pharmaceutical (TSE:4502)

JP3463000004

Takeda Pharmaceutical stock research in summary

Takeda Pharmaceutical shares are less expensive than other comparable stocks. They are good value and show above average growth, but are riskily financed. We recommend evaluating whether the future of the company Takeda Pharmaceutical is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.

Latest Obermatt Ranks


Value Rank	85
Growth Rank	62
Safety Rank	6
Combined Rank	56

Country	Japan
Industry	Pharmaceuticals
Index	Nikkei 225, TOPIX 100
Size class	XX-Large

December 18, 2020. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Filter Similar Stocks

Similar Top 10

☀ Achievements

Top 10 Focus Stock

Family Friendly

Google: Takeda Pharmaceutical

News	Videos
Wikipedia about Takeda Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Takeda Pharmaceutical

RESEARCH HISTORY	2018	2019	2020	2021
VALUE
VALUE	89	88	85	85
GROWTH
GROWTH	71	67	62	62
SAFETY
SAFETY	38	12	6	6
COMBINED
COMBINED	100	57	56	56

Last update of Combined Rank: 18-Dec-2020. Financial reporting date used for calculating ranks: 30-Jun-2020. Stock research history is based on the Obermatt Method. The higher the rank, the better Takeda Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2018	2019	2020	2021
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	66	60	65	65
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	44	29	53	53
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	80	82	78	78
DIVIDEND YIELD
DIVIDEND YIELD	96	98	94	94
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	89	88	85	85

Last update of Value Rank: 18-Dec-2020. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Takeda Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2018	2019	2020	2021
REVENUE GROWTH
REVENUE GROWTH	33	88	96	96
PROFIT GROWTH
PROFIT GROWTH	71	60	26	26
STOCK RETURNS
STOCK RETURNS	57	32	51	51
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	71	67	62	62

Last update of Growth Rank: 30-Jun-2020. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Takeda Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2018	2019	2020	2021
LEVERAGE
LEVERAGE	12	8	8	8
REFINANCING
REFINANCING	28	38	47	47
LIQUIDITY
LIQUIDITY	62	31	31	31
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	38	12	6	6

Last update of Safety Rank: 11-Dec-2020. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Takeda Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Takeda Pharmaceutical from December 18, 2020.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.